Migraine Preventive Treatment Failure: A Cross-Sectional Study in a Tertiary Center in Brazil
DOI:
https://doi.org/10.48208/HeadacheMed.2023.39Keywords:
Migraine, Preventive Therapy, Treatment Failure, Healthcare Resources, Disease BurdenAbstract
Background
In Brazil, there is a scarcity of evidence on migraine burden in patients who have experienced previous preventive treatment failure (PPTF).
Objective
To evaluate the associations between ≥ 3 PPTF and clinical, psychiatric, and medical history data.
Methods
In a retrospective, cross-sectional study, the medical records of migraine patients who first visited a tertiary specialized clinic were examined. We selected adults of both sexes aged ≥ 18 who attended their first appointment between March and July 2017. Ordinal logistic regression models estimated the associations between number of PPTF (no previous treatment, 1 PPTF, 2, and ≥ 3 PPTF) and chronic migraine, the number of diagnosis exams performed, abortive drugs classes used, and non-pharmacological treatments tried (all categorized as none, 1- 3, and ≥ 4), and severe depression (PHQ-9 ≥ 15) and anxiety (GAD-7 ≥ 15), adjusted for sex, age, and years with disease.
Results
Data from 440 patients (72.1 % female) with a mean (SD) age of 37.3 (13.0) years were analyzed. The frequency of no previous treatment was 37.7 % (166/440), while 31.8 % (140/440) showed ≥ 3 PPTF. In patients with ≥ 3 PPTF, 35.7 % (50/140) had episodic, and 64.3 % (90/140) had chronic migraine. Compared to no previous treatment, patients with ≥ 3 PPTF showed higher odds (95 % confidence interval) for chronic migraine [2.10 (1.47, 2.98)], ≥ 4 diagnosis exams [6.59 (3.38, 12.84)], ≥ 4 abortive drug classes [16.03 (9.53, 26.94)], ≥ 4 non-pharmacological treatments [5.91 (3.07,11.35)], and severe depression [1.75 (1.07, 2.88)] and anxiety [1.73 (1.05, 2.85)].
Conclusion
Patients first visiting a headache specialist had a high frequency of non-response treatment associated with higher migraine burden in terms of chronification, psychiatric comorbidity, acute medication and non-pharmacological treatment inefficacy, and unnecessary exams.
Downloads
References
.Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38(1):1-211 Doi: 10.1177/0333102417738202 DOI: https://doi.org/10.1177/0333102417738202
.Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, . . . Murray CJL. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 2018;17(11):954-976 Doi: 10.1016/s1474-4422(18)30322-3 DOI: https://doi.org/10.1016/S1474-4422(18)30322-3
.Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA and Zukerman E. A Nationwide Population-Based Study of Migraine in Brazil. Cephalalgia 2009;29(6):642-649 Doi: 10.1111/j.1468-2982.2008.01782.x DOI: https://doi.org/10.1111/j.1468-2982.2008.01782.x
.Oliveira AB, Queiroz LP, Sampaio Rocha-Filho P, Sarmento EM and Peres MFP. Annual indirect costs secondary to headache disability in Brazil. Cephalalgia 2019;40(6):597-605 Doi: 10.1177/0333102419889357 DOI: https://doi.org/10.1177/0333102419889357
.Kneipp SM, Beeber LL and Linnan LA. Headache and Health-Related Job Loss Among Disadvantaged Women. The Journal for Nurse Practitioners 2014;10(5):316-324 Doi: 10.1016/j.nurpra.2014.02.010 DOI: https://doi.org/10.1016/j.nurpra.2014.02.010
.Buse DC, Pozo-Rosich P, Dupont-Benjamin L, Balkaran BL, Lee L, Jauregui A, . . . Reuter U. Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment. The Journal of Headache and Pain 2023;24(1):Doi: 10.1186/s10194-023-01655-5 DOI: https://doi.org/10.1186/s10194-023-01655-5
.Melhado EM, Santos PSF, Kaup AO, Costa ATNMd, Roesler CAdP, Piovesan ÉJ, . . . Fragoso YD. Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I. Arquivos de Neuro-Psiquiatria 2022;80(08):845-861 Doi: 10.1055/s-0042-1756441 DOI: https://doi.org/10.1055/s-0042-1756441
.Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN and Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2014;35(6):478-488 Doi: 10.1177/0333102414547138 DOI: https://doi.org/10.1177/0333102414547138
.Lee MJ, Al-Karagholi MA-M and Reuter U. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia 2023;43(2):Doi: 10.1177/03331024221146315 DOI: https://doi.org/10.1177/03331024221146315
.Peres MFP, Oliveira AB, Sarmento EM, Rocha-Filho PS, Peixoto PM, Kowacs F, . . . Bensenor IJ. Public policies in headache disorders: needs and possibilities. Arquivos de Neuro-Psiquiatria 2020;78(1):50-52 Doi: 10.1590/0004-282x20190144 DOI: https://doi.org/10.1590/0004-282x20190144
.Kroenke K, Spitzer RL and Williams JBW. The PHQ-9. Journal of General Internal Medicine 2001;16(9):606-613 Doi: 10.1046/j.1525-1497.2001.016009606.x DOI: https://doi.org/10.1046/j.1525-1497.2001.016009606.x
.Sousa TV, Viveiros V, Chai MV, Vicente FL, Jesus G, Carnot MJ, . . . Ferreira PL. Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health and Quality of Life Outcomes 2015;13(1):Doi: 10.1186/s12955-015-0244-2 DOI: https://doi.org/10.1186/s12955-015-0244-2
.Peres MFP, Swerts DB, de Oliveira AB and Silva-Neto RP. Migraine patients’ journey until a tertiary headache center: an observational study. The Journal of Headache and Pain 2019;20(1):Doi: 10.1186/s10194-019-1039-3 DOI: https://doi.org/10.1186/s10194-019-1039-3
.Érica CS, Juliane PPM, André MSS, Rosana TM, Pamella FD, Arao BO and Mario FPP. The impact of anxiety and depression on migraine patients’ journey to a tertiary headache center. Headache Medicine 2019;10(4):174-181 Doi: 10.48208/HeadacheMed.2019.25 DOI: https://doi.org/10.48208/HeadacheMed.2019.25
.Pozo-Rosich P, Lucas C, Watson DPB, Gaul C, Ramsden E, Ritter S, . . . Snellman J. Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. Pain and Therapy 2021;10(2):1691-1708 Doi: 10.1007/s40122-021-00331-3 DOI: https://doi.org/10.1007/s40122-021-00331-3
.Newman L, Vo P, Zhou L, Lopez Lopez C, Cheadle A, Olson M and Fang J. Health Care Utilization and Costs in Patients With Migraine Who Have Failed Previous Preventive Treatments. Neurology Clinical Practice 2021;11(3):206-215 Doi: 10.1212/cpj.0000000000001076 DOI: https://doi.org/10.1212/CPJ.0000000000001076
.Peres MFP, Valença MM, Andrade JR and Santos ERR. Social Determinants of Health and its Role in Headache Disorders. Headache Medicine 2022;12(3):152-153 Doi: 10.48208/HeadacheMed.2021.28 DOI: https://doi.org/10.48208/HeadacheMed.2021.28
.Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S and Lynch W. Health, Absence, Disability, and Presenteeism Cost Estimates of Certain Physical and Mental Health Conditions Affecting U.S. Employers. Journal of Occupational and Environmental Medicine 2004;46(4):398-412 Doi: 10.1097/01.jom.0000121151.40413.bd DOI: https://doi.org/10.1097/01.jom.0000121151.40413.bd
.Yamada AML and Mercante JPP. The bidirectional relation of migraine and affective disorders. Headache Medicine 2022;13(2):145-147 Doi: 10.48208/HeadacheMed.2022.12 DOI: https://doi.org/10.48208/HeadacheMed.2022.12
.Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, . . . Sperling B. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. The Journal of Headache and Pain 2022;23(1):Doi: 10.1186/s10194-022-01521-w DOI: https://doi.org/10.1186/s10194-022-01521-w
.Sakai F, Igarashi H, Yokoyama M, Begasse de Dhaem O, Kato H, Azuma Y, . . . Miyake H. Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees. Cephalalgia 2023;43(4):Doi: 10.1177/03331024231165682 DOI: https://doi.org/10.1177/03331024231165682
.Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, . . . Dodick DW. Migraine: integrated approaches to clinical management and emerging treatments. The Lancet 2021;397(10283):1505-1518 Doi: 10.1016/s0140-6736(20)32342-4 DOI: https://doi.org/10.1016/S0140-6736(20)32342-4
.Lisicki M, Souza MNP, de Oliveira AB, Rubio-Beltrán E, Labastida-Ramirez A, Ashina M and Peres M. Bridging the gaps of headache care for underserved populations: Current status of the headache field in Latin America. Cephalalgia 2022;42(10):1086-1090 Doi: 10.1177/03331024221093623 DOI: https://doi.org/10.1177/03331024221093623
.Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, . . . Mikol DD. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 2018;38(10):1611-1621 Doi: 10.1177/0333102418788347 DOI: https://doi.org/10.1177/0333102418788347
.Wang X, Wen D, He Q, You C and Ma L. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. The Journal of Headache and Pain 2022;23(1):Doi: 10.1186/s10194-022-01472-2 DOI: https://doi.org/10.1186/s10194-022-01472-2
.Peres MFP, Amado DK, Gonçalves AL, Ribeiro R, Pagura JR and Queiroz LPd. The need for preventive therapy in primary headaches. Headache Medicine 2011;2(2):46-49 Doi: 10.48208/HeadacheMed.2011.10 DOI: https://doi.org/10.48208/HeadacheMed.2011.10
.Do TP, Dømgaard M, Stefansen S, Kristoffersen ES, Ashina M and Hansen JM. Barriers and gaps in headache education: a national cross-sectional survey of neurology residents in Denmark. BMC Medical Education 2022;22(1):Doi: 10.1186/s12909-022-03299-6 DOI: https://doi.org/10.1186/s12909-022-03299-6
.Hepp Z, Bloudek LM and Varon SF. Systematic Review of Migraine Prophylaxis Adherence and Persistence. Journal of Managed Care Pharmacy 2014;20(1):22-33 Doi: 10.18553/jmcp.2014.20.1.22 DOI: https://doi.org/10.18553/jmcp.2014.20.1.22
.Oliveira A, Bensenor I, Goulart A, Mercante J and Peres M. Socioeconomic and geographic inequalities in headache disability in Brazil: The 2019 National Health Survey. Headache: The Journal of Head and Face Pain 2023;63(1):114-126 Doi: 10.1111/head.14462 DOI: https://doi.org/10.1111/head.14462
.Ruff DD, Ford JH, Tockhorn-Heidenreich A, Sexson M, Govindan S, Pearlman EM, . . . Aurora SK. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia 2019;39(8):931-944 Doi: 10.1177/0333102419847957 DOI: https://doi.org/10.1177/0333102419847957
.Ruff DD, Ford JH, Tockhorn‐Heidenreich A, Stauffer VL, Govindan S, Aurora SK, . . . Goadsby PJ. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. European Journal of Neurology 2019;27(4):609-618 Doi: 10.1111/ene.14114 DOI: https://doi.org/10.1111/ene.14114
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Arão Belitardo Oliveira, Eduardo Almeida Guimarães Nogueira, Mario Fernando Prieto Peres (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
